• Alexza Pharmaceuticals Inc., of Mountain View, Calif., submitted a marketing authorization application to the European Medicines Agency for its Adasuve (loxapine) for the rapid control of agitation in adult patients with schizophrenia or bipolar disorder. Adasuve uses Alexza's Staccato oral inhalation technology. Grupo Ferrer International SA, of Barcelona, Spain, has commercial rights to Adasuve in Europe, Latin America, Russia and the Commonwealth of Independent States.